Skip to Main text

Investor Relations

Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.

Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.

What's New RSS

The Nitto website is currently under system maintenance. Please try again later.
2016/Nov/11 Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH
2016/Nov/02 Initiation of Phase I Clinical Trial for Seasonal Influenza HA Vaccine Sublingual Tablet
2016/Oct/31 Notice Regarding Dividends from Surplus and Revision of Dividend Forecast
Notice
 
Please be advised that except for current and past facts, the performance outlooks and business strategies presented in this Website are based on projections and judgments by NITTO DENKO management, and may differ from the actual performance.

Moreover, as it is not the intention of this Website to solicit any investments in NITTO DENKO stocks, visitors intending to do so are advised to make their investment decisions solely based on their own judgment.

Back to Page Top